Cancer many of clinical test of remedy in dead end

　The cancer where the promising result is obtained (the cancer) among IIth phase clinical tests of remedy, as for advancing to IIIth phase test just being little, was ascertained by the research of Canada and University of Toronto Ian Tannock doctors, the American cancer remedy academic society annual meeting which in June is held in Chicago (ASCO 2007) with was reported.

　The medicine which passes animal experiment reaches in the clinical place until, Ith phase, IIth phase, IIIth phase (phase there are 3 stages of I, II and III) test. As for Ith phase test, with the small-numbered subject safety of remedy and those which see the safe dosage quantity. As for IIth phase test, usually targeting 100 people or less, those which are seen the remedy in the cancer of specification which effective. When the satisfactory result is produced with IIth phase test, it advances to IIIth phase test. The large random (the random) it allots IIIth phase test, being something which compares the effect of standard cure with the new medicine, it requires huge fund. The american food medical supply bureau (FDA), the satisfactory result at IIIth phase is necessary in approval.

　In the latest research, the result of inspecting the IIth phase test 200 case where the promising result is recognized the breast and the lung, the digestive organs, the 泌 urine genital organ, concerning the cancer of gynecology, as for advancing to IIIth phase test only 13% clarification. As for many, you cannot obtain fund, it was not executed in the reason such that number of the necessary patients does not get together.

　Also it became clear for the case where however, this kind of restriction is recognized at planned point in time of IIth phase test to be many. As for Tannock, unless it advances first, while knowing, as for executing, you say that is, because there is a purpose, success of the researcher. Promotion of the cancer medical specialist depends on the announcement of dissertation, as for IIth phase test in order to do relatively at the number of dwarfs, the young researcher to the possibility being accustomed the “head researcher” is high in comparison with IIIth phase test. But, when it is not the case that the researcher has been conscious of that, the system so it points, Tannock has expressed.

　According to a certain researcher, among the United States execution of IIth phase test is much many in comparison with Europe. Between the doctors where the United States is young in addition to being the pressure which “Publish or Perish (writes dissertation, or in order to save the large amount cost which the medicine manufacture company focuses on IIIth phase test it disappears or)” with it says, on the basis of the result of small-scale IIth phase test, there are also times when already use outside adaptation of the FDA approval being completed medicine is encouraged. In addition, also the point which is difficult to gather the interest whose IIth phase test is wide simply is pointed out.

　Richard Schilsky doctor of ASCO and the circumstance “of Publish or Perish” has recognized IIth phase test excessive cause, a better remuneration system being necessary vis-a-vis the researcher who carries out important role in large-scale IIIth phase test, the general person the result of IIth phase test points out in order to catch prudently.